Your browser doesn't support javascript.
loading
Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
Robertson, John F R; Paridaens, Robert J; Lichfield, Jasmine; Bradbury, Ian; Campbell, Christine.
Afiliação
  • Robertson JFR; Division of Medical Sciences & Graduate Entry Medicine, University of Nottingham, School of Medicine, Nottingham, UK. Electronic address: john.robertson@nottingham.ac.uk.
  • Paridaens RJ; Department of Oncology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium.
  • Lichfield J; Global Medicines Development, AstraZeneca, Cambridge, UK.
  • Bradbury I; Biostatistics, Frontier Science, Kincraig, Scotland, UK.
  • Campbell C; Biostatistics, Frontier Science, Kincraig, Scotland, UK.
Eur J Cancer ; 145: 19-28, 2021 03.
Article em En | MEDLINE | ID: mdl-33418233

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tamoxifeno / Neoplasias da Mama / Receptores de Estrogênio / Pós-Menopausa / Moduladores Seletivos de Receptor Estrogênico / Inibidores da Aromatase Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tamoxifeno / Neoplasias da Mama / Receptores de Estrogênio / Pós-Menopausa / Moduladores Seletivos de Receptor Estrogênico / Inibidores da Aromatase Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2021 Tipo de documento: Article